<table border="0" cellpadding="0" cellspacing="0" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 6:     Effect of Other Drugs on Voriconazole Pharmacokinetics [see Clinical Pharmacology (<linkhtml href="#Section_12.3">12.3</linkhtml>)] 
			</caption>
<tfoot>
<tr>
<td align="justify" colspan="3">
<sup>**</sup> Results based on <content stylecode="italics">in vivo</content> clinical studies generally following repeat oral dosing with 200 mg q12h voriconazole to healthy subjects<br/>
<sup>**</sup> Results based on <content stylecode="italics">in vivo</content> clinical study following repeat oral dosing with 400 mg q12h for 1 day, then 200 mg q12h for at least 2 days voriconazole to healthy subjects<br/>*** Non-Nucleoside Reverse Transcriptase Inhibitors<br/>
</td>
</tr>
</tfoot>
<tbody>
<tr stylecode="Botrule">
<td align="center" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Drug/Drug Class </content>
<br/>
<content stylecode="bold">(Mechanism of Interaction by the Drug)</content>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">Voriconazole Plasma Exposure </content>
<br/>
<content stylecode="bold">(C<sub>max</sub> and AUC</content>
<content stylecode="bold">
<sub>τ</sub>
</content>
<content stylecode="bold"> after 200 mg q12h)</content>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">Recommendations for Voriconazole Dosage Adjustment/Comments</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Rifampin<sup>*</sup> and Rifabutin<sup>*</sup>
<br/>(CYP450 Induction)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Significantly Reduced<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">Contraindicated</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Efavirenz (400 mg q24h)<sup>**</sup>
<br/>(CYP450 Induction) <br/> <br/>Efavirenz (300 mg q24h)<sup>**</sup>
<br/>(CYP450 Induction) <br/> <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Significantly Reduced<br/> <br/> <br/>Slight Decrease in <content stylecode="bold"> </content>AUC<content stylecode="bold">
<sub>τ</sub>
</content>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">Contraindicated</content>
<br/> <br/> <br/>When voriconazole is coadministered with efavirenz, voriconazole oral maintenance dose should be increased to 400 mg q12h and efavirenz should be decreased to 300 mg q24h<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">High-dose Ritonavir (400 mg q12h)<sup>**</sup> (CYP450 Induction) <br/> <br/>Low-dose Ritonavir (100 mg q12h)<sup>**</sup> (CYP450 Induction)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Significantly Reduced <br/> <br/> <br/>Reduced<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">Contraindicated</content>
<br/>
<content stylecode="bold"> </content>
<br/>
<br/>            Coadministration of voriconazole and low-dose ritonavir (100 mg q12h) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Carbamazepine <br/>(CYP450 Induction)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Not Studied <content stylecode="italics">In Vivo </content>or <content stylecode="italics">In Vitro</content>, but Likely to Result in Significant Reduction<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">Contraindicated</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Long Acting Barbiturates <br/>(CYP450 Induction)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Not Studied <content stylecode="italics">In Vivo </content>or <content stylecode="italics">In Vitro</content>, but Likely to Result in Significant Reduction<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">Contraindicated</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Phenytoin<sup>*</sup>
<br/>(CYP450 Induction)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Significantly Reduced<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Increase voriconazole maintenance dose from 4 mg/kg to 5 mg/kg IV q12h or from 200 mg to 400 mg orally q12h (100 mg to 200 mg orally q12h in patients weighing less than 40 kg)<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">St. John’s Wort <br/>(CYP450 inducer; P-gp inducer)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Significantly Reduced<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">Contraindicated</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Oral Contraceptives<sup>**</sup> containing ethinyl estradiol and norethindrone (CYP2C19 Inhibition)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Increased<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Monitoring for adverse events and toxicity related to voriconazole is recommended when coadministered with oral contraceptives<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Fluconazole<sup>**</sup> (CYP2C9, CYP2C19 and CYP3A4 Inhibition) <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Significantly Increased<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Avoid concomitant administration of voriconazole and fluconazole. Monitoring for adverse events and toxicity related to voriconazole is started within 24 h after the last dose of fluconazole.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Other HIV Protease Inhibitors (CYP3A4 Inhibition) <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="italics">In Vivo </content>Studies Showed No Significant Effects of Indinavir on Voriconazole Exposure<br/> <br/>
<content stylecode="italics">In Vitro </content>Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism (Increased Plasma Exposure)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">No dosage adjustment in the voriconazole dosage needed when coadministered with indinavir<br/> <br/>Frequent monitoring for adverse events and toxicity related to voriconazole when coadministered with other HIV protease inhibitors<br/> <br/>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule" valign="top">Other NNRTIs<sup>***</sup>
<br/>(CYP3A4 Inhibition or CYP450 Induction) <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="italics">In Vitro </content>Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism by Delavirdine and Other NNRTIs (Increased Plasma Exposure)<br/> <br/>A Voriconazole-Efavirenz Drug Interaction Study Demonstrated the Potential for the Metabolism of Voriconazole to be Induced by Efavirenz and Other NNRTIs (Decreased Plasma Exposure)<br/> <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Frequent monitoring for adverse events and toxicity related to voriconazole<br/> <br/> <br/> <br/> <br/>Careful assessment of voriconazole  effectiveness<br/> <br/>
</td>
</tr>
</tbody>
</table>